Related references
Note: Only part of the references are listed.Rapid virologic response: A new milestone in the management of chronic hepatitis C
Fred Poordad et al.
CLINICAL INFECTIOUS DISEASES (2008)
Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: A randomized trial
Ming-Lung Yu et al.
HEPATOLOGY (2008)
Rapid virological response is a more important predictor of sustained virological response (SVR) than genotype in patients with chronic hepatitis C virus infection
M. W. Fried et al.
JOURNAL OF HEPATOLOGY (2008)
Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial
Alessandra Mangia et al.
HEPATOLOGY (2008)
Predictors of treatment in patients with chronic hepatitis C infection - Role of patient versus nonpatient factors
Fasiha Kanwal et al.
HEPATOLOGY (2007)
Impact of Asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C
Sharif Missiha et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2007)
Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the 'accordion' regimen?
Patrick Marcellin et al.
JOURNAL OF HEPATOLOGY (2007)
Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: A randomized trial
Ira M. Jacobson et al.
HEPATOLOGY (2007)
Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1
Ira M. Jacobson et al.
HEPATOLOGY (2007)
Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha
Mitchell L. Shiffman et al.
HEPATOLOGY (2007)
Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection
G. W. McCaughan
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2007)
Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin
Jian-Wu Yu et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2007)
Early viral kinetics during treatment of chronic hepatitis C virus infection with pegylated interferon alpha plus ribavirin in Taiwan
Ching-Sheng Hsu et al.
INTERVIROLOGY (2007)
Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin
Eric Snoeck et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin
Jean-Pierre Bronowicki et al.
GASTROENTEROLOGY (2006)
Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment
Jose M. Sanchez-Tapias et al.
GASTROENTEROLOGY (2006)
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1
Hari S. Conjeevaram et al.
GASTROENTEROLOGY (2006)
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy
DM Jensen et al.
HEPATOLOGY (2006)
Extended treatment duration for hepatitis C virus type 1: Comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin
T Berg et al.
GASTROENTEROLOGY (2006)
A randomized trial of 24- vs. 48-week courses of PEG interferon α-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients:: a pilot study in Taiwan
ML Yu et al.
LIVER INTERNATIONAL (2006)
Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia
S Zeuzem et al.
JOURNAL OF HEPATOLOGY (2006)
Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C
Y Iwasaki et al.
HEPATOLOGY (2006)
Comparison of a 6-month course peginterferon α-2b plus ribavirin and interferon α-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan
SD Lee et al.
JOURNAL OF VIRAL HEPATITIS (2005)
High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C
K Lindahl et al.
HEPATOLOGY (2005)
Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C -: A randomized study of treatment duration and ribavirin dose
SJ Hadziyannis et al.
ANNALS OF INTERNAL MEDICINE (2004)
Differences in treatment outcome for hepatitis C among ethnic groups
MJ Hepburn et al.
AMERICAN JOURNAL OF MEDICINE (2004)
Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites
AJ Muir et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon
E Herrmann et al.
HEPATOLOGY (2003)
Southeast Asian patients with chronic hepatitis C: The impact of novel genotypes and race on treatment outcome
AT Dev et al.
HEPATOLOGY (2002)
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
MW Fried et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin
M Buti et al.
HEPATOLOGY (2002)
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
MP Manns et al.
LANCET (2001)
Medical progress: Hepatitis C virus infection.
GM Lauer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
